Home » What’s New » Ranibizumab and aflibercept account for approximately 12% of the annual Medicare Part B drug budget

Ranibizumab and aflibercept account for approximately 12% of the annual Medicare Part B drug budget

This observational study estimated annual Medicare Part B spending on 2 anti-VEGF drugs.
Source: AAO

Malta, NY
658 Malta Ave, Suite 101
Malta, NY 12020

Troy, NY
2200 Burdett Avenue, Suite 206
Troy, New York 12180

Clifton Park(EyesNY), NY
1712 Route 9,
Halfmoon, NY 12065